108 related articles for article (PubMed ID: 8898105)
1. Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies.
Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Crommelin DJ; Storm G
FEBS Lett; 1996 Oct; 395(2-3):245-50. PubMed ID: 8898105
[TBL] [Abstract][Full Text] [Related]
2. Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy.
Mizuguchi H; Nakanishi M; Nakanishi T; Nakagawa T; Nakagawa S; Mayumi T
Br J Cancer; 1996 Feb; 73(4):472-6. PubMed ID: 8595161
[TBL] [Abstract][Full Text] [Related]
3. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of diphtheria toxin A-chain gene-containing cationic liposomes conjugated with monoclonal antibody directed to tumor-associated antigen of bovine leukemia cells.
Tana ; Watarai S; Onuma M; Aida Y; Kakidani H; Kodama H; Yasuda T
Jpn J Cancer Res; 1998 Nov; 89(11):1202-11. PubMed ID: 9914790
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor effect of cationic liposomes containing diphtheria toxin A-chain gene on cells infected with bovine leukemia virus.
Tana ; Watarai S; Lee JT; Onuma M; Ochiai K; Kakidani H; Yasuda T
J Vet Med Sci; 1997 Jul; 59(7):617-9. PubMed ID: 9271462
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cationic liposomes for delivery of diphtheria toxin A-chain gene to cells infected with bovine leukemia virus.
Lee JT; Watarai S; Kakidani H; Onuma M; Zhao DD; Yasuda T
J Vet Med Sci; 1997 Mar; 59(3):169-74. PubMed ID: 9101475
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of diphtheria toxin A fragment to toxin-resistant murine cells delivered by pH-sensitive immunoliposomes.
Collins D; Huang L
Cancer Res; 1987 Feb; 47(3):735-9. PubMed ID: 3802078
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
10. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity.
Kageyama T; Ohishi M; Miyamoto S; Mizushima H; Iwamoto R; Mekada E
J Biochem; 2007 Jul; 142(1):95-104. PubMed ID: 17525101
[TBL] [Abstract][Full Text] [Related]
11. Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.
Schmohl JU; Todhunter D; Oh S; Vallera DA
Toxins (Basel); 2015 Oct; 7(10):4067-82. PubMed ID: 26473923
[TBL] [Abstract][Full Text] [Related]
12. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics.
Rodriguez R; Lim HY; Bartkowski LM; Simons JW
Prostate; 1998 Mar; 34(4):259-69. PubMed ID: 9496900
[TBL] [Abstract][Full Text] [Related]
13. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood.
Thompson J; Hu H; Scharff J; Neville DM
J Biol Chem; 1995 Nov; 270(47):28037-41. PubMed ID: 7499288
[TBL] [Abstract][Full Text] [Related]
14. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
15. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
16. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
[TBL] [Abstract][Full Text] [Related]
17. Colloidal systems for tumor targeting.
Storm G; Crommelin DJ
Hybridoma; 1997 Feb; 16(1):119-25. PubMed ID: 9085138
[TBL] [Abstract][Full Text] [Related]
18. Study on the variables affecting toxicity of hybrid toxins. The effect of different target cell receptor distribution and toxin binding chain.
Chang TM; Chang CH
Biochim Biophys Acta; 1989 Oct; 1013(3):239-46. PubMed ID: 2804085
[TBL] [Abstract][Full Text] [Related]
19. Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
Liang B; Shahbaz M; Wang Y; Gao H; Fang R; Niu Z; Liu S; Wang B; Sun Q; Niu W; Liu E; Wang J; Niu J
Clin Cancer Res; 2015 Mar; 21(5):1183-95. PubMed ID: 25549721
[TBL] [Abstract][Full Text] [Related]
20. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Dekker LC; Van Hoesel QG; Crommelin DJ; Storm G
Br J Cancer; 1996 Oct; 74(7):1023-9. PubMed ID: 8855969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
